Mixed Treatment Comparisons, Network Meta-Analysis (NMA)

Read More

 

Health Economics Modeling: Cost-Effectiveness, Budget Impact (HAS CEESP, CEPS)

Read More

 

Real Life Medico-Economic Studies (SNDS)

Read More

 

Open Data and Data science

Read More

 

Health economics and Statistics

Welcome!

Statésia is a research and consulting firm specialized in comparative effectiveness research and medico-economic analysis of health products, technologies and strategies (for HAS CT, HAS CEESP, CEPS submissions).

This decision analysis is founded on:

1- Comparative Effectiveness Research, Indirect and Mixed Treatment Comparisons (MTC, NMA) : Positioning your innovative technology in the studied therapeutic area;

2- Interactive Health Economics Modeling: Assessing the cost-effectiveness, the cost-utility or the cost-benefit of your innovative health product or technology;

3- Interactive Budget Impact Analysis (IBIA) : Assessing the affordability of your innovative product.

 

FaLang translation system by Faboba

News

PublicationMaunoury F1,2, Drugeon B3, Boisson M4,5, Marjanovic N3, Couvreur R3,4, Mimoz O3,4,6, Guenezan J3,4,6, on behalf of the CLEAN-3 Study. Cost-effectiveness analysis of bundled innovative devices versus standard approach in the prevention of unscheduled peripheral venous catheters removal due to complications in France. PLoS One. 2022.

1 Statesia, Le Mans, France; 2 University of Le Mans, GAINS, IRA, Le Mans, France; 3 University Hospital of Poitiers, Emergency Department and Pre-Hospital Care, France; 4 University of Poitiers, School of Medicine and Pharmacy, Poitiers, France; 5 University Hospital of Poitiers, Anesthesia, Intensive Care and Peri-Operative Medicine Department, France; 6 INSERM U1070, Pharmacology of anti-infective drugs, Poitiers, France.

PublicationMaunoury F1, Oury A2, Fortin S2, Thomassin L3, Bohbot S3; Explorer Study. Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France. PLoS One. 2021 Jan 22;16(1):e0245652. doi: 10.1371/journal.pone.0245652. PMID: 33481840; PMCID: PMC7822547.

1 Health Economics, Statesia, Le Mans, France. 2 Global Regulatory Affairs & Market Access, URGO Medical, Chenôve, France. 3 Global Medical Affairs, URGO Medical, Paris, France.

PublicationSalah Ghabri PhD1, Aymeric Binard MD2, Yves-Marie Pers MD3, Franck Maunoury PhD4, J. Jaime Caro MD,CM, FRCPC, FACP567. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France. Value in Health DOI: https://doi.org/10.1016/j.jval.2019.12.003. Available online 13 February 2020.

1 Department of Economic and Public Health Evaluation, French National Authority for Health (HAS), Saint-Denis La Plaine, France 2 Department of Rheumatology, CHU de la Cavale-Blanche, Brest, France 3 Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital, Montpellier, France 4 STATESIA, Le Mans, France 5 McGill University, Montreal, QC, Canada 6 London School of Economics, London, England, UK 7 Evidera, Boston, MA, USA .

PublicationGordon Goodall1, Mark Lamotte2, Mafalda Ramos2, Franck Maunoury3, Barbora Pejchalova1, Gérard de Pouvourville4 (2019). Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients, Journal of Medical Economics, DOI: 10.1080/13696998.2018.1559600.

1 Edwards Lifesciences S.A., Route de l'Etraz 70, 1260 Nyon, Switzerland, 2 IQVIA Corporate village, Davos building, Da Vincilaan 7, 1930 Zaventem, Belgium, 3 STATESIA, 19 Boulevard Marie et Alexandre Oyon, 72100 Le Mans, France, 4 ESSEC Business School, Av. Bernard Hirsch, B.P. 50105, 95021 Cergy Pontoise Cedex, France

 

top arrow